

## LifeSci Biotechnology Clinical Trials Index

1/20/2021

Effective at the market close on Thursday January 21, **EIDX and PRVL will be removed from the LifeSci Biotechnology Clinical Trials Index** and their values will be redistributed to the remaining index components based on their weights.

- On October 5, 2020, Eidos agreed to be acquired by BridgeBio for a combination of cash and stock.
- On December 15, 2020, Prevail agreed to be acquired by Eli Lilly for \$26.50/share in cash.